MTNB
Matinas BioPharma Holdings, Inc.Substantial doubt about the company's ability to continue as a going concern.
“The Company does not believe that the cash and cash equivalents on hand are sufficient to fund planned operations for a period of at least twelve months from the filing date of these financial statements. As a result, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 8, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-04-30 | D An Evelyn |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. |
Stock Option (right to Buy)
|
11,600 |
| 2025-04-30 | Murphy Keith |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. |
Stock Option (right to Buy)
|
11,600 |
| 2025-04-30 | Smith Robin L |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. |
Stock Option (right to Buy)
|
11,600 |
| 2025-04-30 | Jabbour Jerome D |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. The options vest, subject to stockholder approval of the 2025 Plan, as to 25% of the shares on April 30, 2026 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing April 30, 2026. |
Stock Option (right to Buy)
|
70,100 |
| 2025-04-30 | NEUGEBOREN EDWARD |
Director |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. |
Stock Option (right to Buy)
|
11,600 |
| 2025-04-08 | Pembroke & Partners LLC |
10% Owner |
Other↑
|
No Securities Owned
|
0 |
| 2025-04-08 | Sanitam Partners LLC |
10% Owner |
Other↑
|
No Securities Owned
|
0 |
| 2025-03-11 | Murphy Keith |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-03-11 | NEUGEBOREN EDWARD |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-13 | Smith Robin L |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-05 | D An Evelyn |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2023-12-15 | Matkovits Theresa |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Stock Option (right to Buy)
|
1,300,000 |
| 2023-12-15 | Kucinski Keith A |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Stock Option (right to Buy)
|
1,000,000 |
| 2023-12-15 | Hoover Thomas |
Chief Business Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Stock Option (right to Buy)
|
1,000,000 |
| 2023-12-15 | Jabbour Jerome D |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Stock Option (right to Buy)
|
3,500,000 |
| 2023-12-15 | Liu Hui |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Stock Option (right to Buy)
|
1,000,000 |
| 2023-12-15 | Ferguson James J. III |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Stock Option (right to Buy)
|
1,200,000 |
| 2023-11-01 | Giordano Natasha |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
437,244 |
| 2023-11-01 | Ende Eric J |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
437,244 |
| 2023-11-01 | Scibetta James S |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
437,244 |
| 2023-11-01 | WIKLER MATTHEW |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
437,244 |
| 2023-11-01 | Corzo Kathryn Penkus |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
437,244 |
| 2023-11-01 | CONRAD HERBERT J |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
437,244 |
| 2022-12-20 | Ferguson James J. III |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. |
Stock Option (right to Buy)
|
625,000 |
| 2022-12-20 | Jabbour Jerome D |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. |
Stock Option (right to Buy)
|
1,988,300 |
| 2022-12-20 | Liu Hui |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. |
Stock Option (right to Buy)
|
625,000 |
| 2022-12-20 | Hoover Thomas |
Chief Business Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. |
Stock Option (right to Buy)
|
475,000 |
| 2022-12-20 | Kucinski Keith A |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. |
Stock Option (right to Buy)
|
625,000 |
| 2022-12-20 | Matkovits Theresa |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. |
Stock Option (right to Buy)
|
625,000 |
| 2022-11-14 | Giordano Natasha |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
142,657 |
| 2022-11-14 | Corzo Kathryn Penkus |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
142,657 |
| 2022-11-14 | WIKLER MATTHEW |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
142,657 |
| 2022-11-14 | CONRAD HERBERT J |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
142,657 |
| 2022-11-14 | Ende Eric J |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
142,657 |
| 2022-11-14 | Scibetta James S |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
142,657 |
| 2022-06-22 | CONRAD HERBERT J |
Director |
Gift↑
|
Common Stock, par value $0.0001 per share
(I)
|
1,358,122 |
| 2022-06-22 | CONRAD HERBERT J |
Director |
Gift↓
|
Common Stock, par value $0.0001 per share
(I)
|
1,358,122 |
| 2021-12-31 | WIKLER MATTHEW |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
On December 31, 2021, the Reporting Person was issued 7,859 shares of common stock, par value $0.0001 per share, pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant. |
Common Stock
|
7,859 |
| 2021-12-14 | Matkovits Theresa |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Stock Option (right to Buy)
|
500,000 |
| 2021-12-14 | Jabbour Jerome D |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Stock Option (right to Buy)
|
1,658,100 |
| 2021-12-14 | MANNINO RAPHAEL J |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Stock Option (right to Buy)
|
275,000 |
| 2021-12-14 | Hoover Thomas |
Chief Business Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Stock Option (right to Buy)
|
850,000 |
| 2021-12-14 | Kucinski Keith A |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Stock Option (right to Buy)
|
500,000 |
| 2021-12-14 | Ferguson James J. III |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Stock Option (right to Buy)
|
587,600 |
| 2021-12-14 | Liu Hui |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (right to Buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Stock Option (right to Buy)
|
275,000 |
| 2021-12-06 | Hoover Thomas |
Chief Business Officer |
Other↑
|
No Securities Owned
|
0 |
| 2021-11-01 | Giordano Natasha |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
90,882 |
| 2021-11-01 | WIKLER MATTHEW |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
90,882 |
| 2021-11-01 | Scibetta James S |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
90,882 |
| 2021-11-01 | Corzo Kathryn Penkus |
Director |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 36 months commencing on November 30, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Stock option (right to buy)
|
181,763 |